American Association for Cancer Research
23266066cir150099t-sup-148106_1_supp_3041722_nqrx4x.png (131 kB)

Suppl fig 3 from Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing

Download (131 kB)
posted on 2023-04-03, 23:00 authored by Arianne M. Brandsma, Toine ten Broeke, Maaike Nederend, Laura A.P.M. Meulenbroek, Geert van Tetering, Saskia Meyer, J.H. Marco Jansen, M. Alejandra Beltrán Buitrago, Sietse Q. Nagelkerke, István Németh, Ruud Ubink, Gerard Rouwendal, Stefan Lohse, Thomas Valerius, Jeanette H.W. Leusen, Peter Boross

FcR expression on effector cells. Expression of FcγR and FcαRI expression was measured by flow cytometry using mAbs specific for FcγRI (CD64, clone 10.1), FcγRIIa (CD32, clone IV.3), FcγRIII (CD16, clone 3G8) and FcαRI (CD89, clone A77). Effector cells were identified in leukocytes by the following surface markers: monocytes: CD14+CD16+, PMNs: CD16+ and NK cells: CD3-CD56+.



Efficacy of anticancer monoclonal antibodies (mAb) is limited by the exhaustion of effector mechanisms. IgG mAbs mediate cellular effector functions through FcγRs expressed on effector cells. IgA mAbs can also induce efficient tumor killing both in vitro and in vivo. IgA mAbs recruit FcαRI-expressing effector cells and therefore initiate different effector mechanisms in vivo compared with IgG. Here, we studied killing of tumor cells coexpressing EGFR and HER2 by the IgG mAbs cetuximab and trastuzumab and their IgA variants. In the presence of a heterogeneous population of effector cells (leukocytes), the combination of IgG and IgA mAbs to two different tumor targets (EGFR and HER2) led to enhanced cytotoxicity compared with each isotype alone. Combination of two IgGs or two IgAs or IgG and IgA against the same target did not enhance cytotoxicity. Increased cytotoxicity relied on the presence of both the peripheral blood mononuclear cell and the polymorphonuclear (PMN) fraction. Purified natural killer cells were only cytotoxic with IgG, whereas cytotoxicity induced by PMNs was strong with IgA and poor with IgG. Monocytes, which coexpress FcγRs and FcαRI, also displayed increased cytotoxicity by the combination of IgG and IgA in an overnight killing assay. Coinjection of cetuximab and IgA2-HER2 resulted in increased antitumor effects compared with either mAb alone in a xenograft model with A431-luc2-HER2 cells. Thus, the combination of IgG and IgA isotypes optimally mobilizes cellular effectors for cytotoxicity, representing a promising novel strategy to improve mAb therapy. Cancer Immunol Res; 3(12); 1316–24. ©2015 AACR.

Usage metrics

    Cancer Immunology Research



    Ref. manager